{"entity":{"id":"nct07446855","kind":"trial","name":"Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours","aka":["PARTHENON"],"tldr":"This study tests a PARP inhibitor; the registry reports that it is recruiting.","summary":"The registry lists NCT07446855 as recruiting, last updated 2026-10-01. Enrolment is 180 planned participants, an estimate. Interventions: AZD4956, Saruparib. Primary measures include Parts A and B: Number of participants with adverse events (AEs) and serious adverse events (SAEs); Part B: Progression free survival (PFS). No results are posted in the registry; this does not exclude separate publications.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT07446855","url":"https://clinicaltrials.gov/study/NCT07446855"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["saruparib"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07446855","phase":"1/2","setting":"A Modular Open-label, Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Ascending Doses of AZD4956 as Monotherapy, and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Repair Defective Solid Tumours","sponsor":"AstraZeneca","participation":[{"nct":"NCT07446855","source":"https://clinicaltrials.gov/study/NCT07446855","fetchedAt":"2026-10-07T16:55:45.930Z","studySha256":"f046b5df0b301e4021a9444aafd6a8350ed9c9121cafd685e8b64c6b2a445c17","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-01","leadSponsor":"AstraZeneca","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"130 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":180,"enrolmentType":"ESTIMATED","siteCount":19,"recruitingSiteCount":11,"countries":["Australia","Japan","South Korea","Spain","United Kingdom","United States"]}],"started":"2026-03-17","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07446855/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"saruparib","kind":"drug","name":"Saruparib","route":"/drugs/saruparib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}